About Stimulator of interferon genes protein
Stimulator of interferon genes protein (STING1) is a protein
from Homo sapiens identified by UniProt accession
Q86WV6, 379 residues long.
MolForge cross-references it against 0 known binders and
861 disease associations.
Target properties
| Protein name | Stimulator of interferon genes protein |
| UniProt accession | Q86WV6 |
| Gene | STING1 |
| Organism | Homo sapiens |
| Length | 379 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (861)
Diseases linked to this target (Open Targets).
- STING-associated vasculopathy with onset in infancy · score 0.72
- COVID-19 · score 0.48
- familial chilblain lupus · score 0.37
- severe acute respiratory syndrome · score 0.37
- anti-merkel cell virus antibody measurement · score 0.24
- merkel cell virus seropositivity · score 0.23
- esophageal squamous cell carcinoma · score 0.22
- autoinflammatory syndrome · score 0.19
- genetic disorder · score 0.19
- monocyte percentage of leukocytes · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86WV6-F1 | alphafold | PREDICTED | 83.74 | — |
Amino-acid sequence (379 residues)
MPHSSLHPSI PCPRGHGAQK AALVLLSACL VTLWGLGEPP EHTLRYLVLH LASLQLGLLL NGVCSLAEEL RHIHSRYRGS YWRTVRACLG CPLRRGALLL LSIYFYYSLP NAVGPPFTWM LALLGLSQAL NILLGLKGLA PAEISAVCEK GNFNVAHGLA WSYYIGYLRL ILPELQARIR TYNQHYNNLL RGAVSQRLYI LLPLDCGVPD NLSMADPNIR FLDKLPQQTG DHAGIKDRVY SNSIYELLEN GQRAGTCVLE YATPLQTLFA MSQYSQAGFS REDRLEQAKL FCRTLEDILA DAPESQNNCR LIAYQEPADD SSFSLSQEVL RHLRQEEKEE VTVGSLKTSA VPSTSTMSQE PELLISGMEK PLPLRTDFS
Explore Stimulator of interferon genes protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets